Diseases /

Post-Transplant Lymphoproliferative Disorder

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: Post-transplant lymphoproliferative disorder (PTLD) is a polyclonal (benign) or clonal (malignant) proliferation of lymphoid cells that develops as a consequence of immunosuppression in a recipient of a solid organ or bone marrow allograft. PTLDs comprise a spectrum ranging from early, Epstein-Barr virus (EBV)-driven polyclonal lymphoid proliferations to EBV-positive or EBV- negative lymphomas of predominantly B-cell or less often T-cell type. (WHO, 2001) [1]

Post-transplant lymphoproliferative disorders most frequently harbor alterations in TP53, MCL1, and CBL [2].

Most Commonly Altered Genes in Post-Transplant Lymphoproliferative Disorder

TP53 c.217-c.1178 Missense, TP53 R248Q, TP53 Mutation, TP53 Missense, and TP53 Exon 7 Mutation are the most common alterations in post-transplant lymphoproliferative disorder [2].

Top Alterations in Post-Transplant Lymphoproliferative Disorder

Clinical Trials

View Clinical Trials for Post-Transplant Lymphoproliferative Disorder

Disease Details

Synonyms
PTLD, post-transplant lymphoproliferative disorder, Post-transplant Lymphoproliferative Disorder
Parent(s)
Immunodeficiency-Associated Lymphoproliferative Disorder
Children
Polymorphic Post-Transplant Lymphoproliferative Disorder, Classic Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder, Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder, Infectious Mononucleosis-Like Post-Transplant Lymphoproliferative Disorder, Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder, and Monomorphic Post-Transplant Lymphoproliferative Disorder
OncoTree Name
Posttransplant Lymphoproliferative Disorders
OncoTree Code
PTLD

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.